ClinicalTrials.gg
Not yet recruitingNCT06663124Updated Oct 29, 2024

Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy

An interventional study of EC-DBS ON in Epilepsy, Drug Resistant, sponsored by Xuanwu Hospital, Beijing. Not yet recruiting at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
14 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing — 11 open to participants now, 12 under way, none of them phase 3. Drug Resistant Epilepsy · Xuanwu Hospital, Beijing.

Planned enrollment
7th of 12
10 · median 13
Started
2024
with 11 others
No phase
10 of 15
7 open now
Primary completion
2025-01
later than 0 of 11 live
Registered
8th of 15
by date

Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 12 that started in 2024, is one of 10 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 8th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

11 of the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 14 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

Evaluation of the Efficacy and Safety of Deep Brain Stimulation of the Extreme Capsule (EC) for the Treatment of Drug-Resistant Epilepsy

Read the detailed description

This studyTo evaluate the efficacy and safety of deep brain stimulation of the EC for the treatment of drug-resistant epilepsy originating from EC structurally connected cortex cortex, This study aims to explore stimulation patterns and parameters that can suppress abnormal epileptic discharges at the seizure focus without impairing language function. This study aims to improve treatment challenges for these patients and promote clinical translation and application

03

Conditions studied

  • Epilepsy, Drug Resistant

Keywords

  • Extreme capsule
  • Deep Brain Stimulation
  • Drug Resistant Epilepsy
  • Focal Epilepsy
04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are between the ages of 14 -65 years of age
  • Diagnosis of drug-resistant epilepsy follows the standard of resistance to regular medication treatment for at least two years. Comprehensive preoperative epilepsy assessment, combined with individualized fiber tracking, is used to determine whether the epileptogenic zone is located in cortex regions structurally connected to the extreme capsule.
  • Persistence of disabling seizures at least 3 times per month or greater,
  • signed.

Exclusion criteria

Exclusion Criteria:

  • Structural alterations are present in the extreme capsule.
  • Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations;
  • Psychogenic non-epileptic seizures within 12 months;
  • Presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit;
  • Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications;
  • IQ \< 55 or severe cognitive dysfunction, unable to complete the study;
  • Diagnosed with a progressive neurological disorder (including progressive Rasmussen's encephalitis, etc.);
  • Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty/hospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders;
  • Diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function;
  • Pregnant, or planning to pregnant within 2 years;
  • Participation in another clinical study within 3 months;
  • Not suitable for enrollment as assessed by the multidisciplinary team of the center.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    EC-DBS group

    participants will undergo EC-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.

    Device: EC-DBS ON

Interventions

  • DeviceEC-DBS ON

    The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.

06

What researchers measure

Primary outcomes

  1. Seizure frequency (SF28)

    Seizure frequency (SF28) is defined as seizure count per month (28-day) period. The SF28 is calculated as follows, where D=total number of days for which seizure information is collected for the specific 28-day interval: SF28=(Total number of seizures in D days/D)\*28. In addition, the baseline seizure frequency is defined as mean of 3-month SF28 in the baseline period. The seizure frequency in double-blind phase is defined as SF28 per month during the double-blind period. Percent change in seizure frequency=100\*(double-blind SF28-baseline SF28)/baseline SF28.

    Time frame: Up to 1 year after EC-DBS

Secondary outcomes

  1. Seizure Responder Rate

    The proportion of patients with a ≥ 50% reduction from Baseline in seizure frequency.

    Time frame: Up to 1 year after EC-DBS

  2. Life quality evaluation

    Percentage change from baseline in Quality of Life in Epilepsy-31 inventory (QOLIE-31) score.

    Time frame: Up to 1 year after EC-DBS

  3. Adverse Events

    Rate of adverse events which were judged to be study-related throughout the study.

    Time frame: Up to 1 year after EC-DBS

  4. Incidence of Sudden Unexpected Death in Epilepsy (SUDEP)

    The number presented is for Definite and Probable SUDEP. The rate is calculated per 1000 subject years of follow

    Time frame: Up to 1 year after EC-DBS

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Jan 2025, 2 months later.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 2 months is below that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2024
First posted
Oct 29, 2024
StartEst.
Nov 1, 2024
Primary completionEst.
Jan 1, 2025
CompletionEst.
Nov 1, 2026
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06663124
Responsible party
Liankun_Ren (Professor, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Oct 29, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Jan 1, 2025 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Oct 29, 2024

Study contacts

Liankun Ren, MD
Contact
renlk2022@outlook.com
+86 13681576621
Liankun Ren, MD
principal investigator · Xuanwu Hospital, Beijing

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion